CBLL
CeriBell, Inc. Common StockCBLL
CBLL
About: CeriBell Inc is a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. The Company has developed the Ceribell System, a novel, point-of-care electroencephalography (EEG) platform specifically designed to address the unmet needs of patients in the acute care setting. By combining proprietary, portable and rapidly deployable hardware with sophisticated artificial intelligence (AI) powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions.
Employees: 281
0
Funds holding %
of 7,312 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
53% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 17
21% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 19
10% more funds holding
Funds holding: 78 [Q4 2024] → 86 (+8) [Q1 2025]
2.71% more ownership
Funds ownership: 64.47% [Q4 2024] → 67.17% (+2.71%) [Q1 2025]
0% more funds holding in top 10
Funds holding in top 10: 4 [Q4 2024] → 4 (+0) [Q1 2025]
23% less capital invested
Capital invested by funds: $598M [Q4 2024] → $463M (-$135M) [Q1 2025]
Research analyst outlook
We haven’t received any recent analyst ratings for CBLL.
Financial journalist opinion
Neutral
GlobeNewsWire
4 days ago
Ceribell Files Complaints Against Natus Medical Incorporated with the U.S. International Trade Commission and Federal Court in Delaware
Complaints Assert Infringement of Patents Related to Point-of-Care Electroencephalography (EEG) Technology Complaints Assert Infringement of Patents Related to Point-of-Care Electroencephalography (EEG) Technology
Neutral
GlobeNewsWire
1 month ago
Ceribell to Participate in the William Blair 45th Annual Growth Stock Conference
SUNNYVALE, Calif., May 20, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that Jane Chao, Ph.D., CEO and Co-founder, will present at the upcoming William Blair 45th Annual Growth Stock Conference. The presentation will take place on Tuesday, June 3, 2025, at 7:20 a.m. Pacific Standard Time / 9:20 a.m. Central Standard Time.
Neutral
Seeking Alpha
2 months ago
CeriBell, Inc. (CBLL) Q1 2025 Earnings Call Transcript
CeriBell, Inc. (NASDAQ:CBLL ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Xingjuan Chao - Co-Founder and Chief Executive Officer Scott Blumberg - Chief Financial Officer Conference Call Participants Stephanie Piazzola - Bank of America Margaret Andrew - William Blair Josh Jennings - TD Cowen John Young - Canaccord Jeffrey Cohen - Ladenburg Thalmann Operator Hello, and thank you for standing by. At this time, I would like to welcome you to the CeriBell Q1 2025 Earnings Call.
Neutral
GlobeNewsWire
2 months ago
Ceribell Reports First Quarter 2025 Financial Results
SUNNYVALE, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today reported financial results for the quarter ended March 31, 2025.
Neutral
GlobeNewsWire
2 months ago
Ceribell to Participate in the Bank of America Securities 2025 Health Care Conference
SUNNYVALE, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that Jane Chao, Ph.D., CEO and Co-founder, will present at the upcoming Bank of America Securities 2025 Health Care Conference. The presentation will take place on Wednesday, May 14, 2025, at 10:55 a.m. Pacific Standard Time / 1:55 p.m. Eastern Standard Time.
Neutral
GlobeNewsWire
2 months ago
Ceribell Receives FedRAMP® High Authorization, Expanding Approval for Its AI-Powered Point-of-Care EEG Across Federal Healthcare Systems
Ceribell is one of only 51 companies in the U.S. to achieve FedRAMP High authorization Ceribell's breakthrough technology can now be deployed in federal healthcare facilities, including U.S. Department of Veterans Affairs hospitals, helping clinicians deliver faster diagnosis and treatment for patients at risk of non-convulsive seizures SUNNYVALE, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company transforming the diagnosis and management of patients with serious neurological conditions, announced today that its point-of-care electroencephalogram (EEG) system has received full FedRAMP® (Federal Risk and Authorization Management Program) High authorization from the U.S. government.
Neutral
GlobeNewsWire
2 months ago
Ceribell to Report First Quarter 2025 Financial Results on May 8, 2025
SUNNYVALE, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that it will release financial results for the first quarter of 2025 after the close of trading on Thursday, May 8, 2025.
Neutral
Zacks Investment Research
2 months ago
CBLL Stock Falls Despite FDA Clearance for Pediatric Clarity Algorithm
Ceribell secures FDA clearance for Clarity algorithm in pediatric patients, expanding rapid seizure detection capabilities and enhancing critical care efficiency.
Neutral
GlobeNewsWire
2 months ago
FDA Clears Ceribell's Clarity™ Algorithm for Pediatric Patients, Making Ceribell the First and Only FDA-Cleared AI Technology for Detection of Electrographic Seizures in Patients Ages 1 Year and Older
SUNNYVALE, Calif., April 15, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its next generation Ceribell Clarity™ algorithm for the detection of electrographic seizures in patients ages 1 and older.
Neutral
Seeking Alpha
4 months ago
CeriBell, Inc. (CBLL) Q4 2024 Earnings Call Transcript
CeriBell, Inc. (NASDAQ:CBLL ) Q4 2024 Earnings Conference Call February 25, 2025 4:30 PM ET Company Participants Brian Johnston - Gilmartin Group Xingjuan Chao - President and Chief Executive Officer Scott Blumberg - Chief Financial Officer Conference Call Participants Stephanie Piazzola - Bank of America Robert Marcus - JPMorgan Chase & Co. Macauley Kilbane - William Blair & Company Joshua Jennings - TD Cowen William Plovanic - Canaccord Genuity Corp. Operator Operator Hello, and thank you for standing by. At this time, I would like to welcome you to the CeriBell Q4 2024 Earnings Call.
Charts implemented using Lightweight Charts™